Verdict: KEEP

ORLY is 0.41% of the selectable universe. The cleanest factor profile in the basket — 97.7% idio variance, QQQ beta 0.07. Trailing alpha -2.6% annualized is not statistically significant (t = -0.12). The 1Y underperformance vs QQQ (-18.7pp) is mechanical: near-zero QQQ sensitivity + anti-momentum loading in a high-beta, high-momentum market.

The deep dive found real bear evidence. Self-insurance reserves doubled at the current portion level (+99%, $149M to $297M). Management missed their own SG&A guide by 1.5-2.0pp every quarter of FY2025. The forward multiple embeds ≈20% earnings growth that requires margin expansion management's track record contradicts. Insiders are selling, not buying, at 24% of the 52-week range.

None of this is enough to remove. At 0.41% weight, maximum plausible filtration benefit is 3-5 bps — below noise. The business is fundamentally sound (33 years of SSS growth, professional comps >10%, clear sector winner vs AZO/GPC). Remove requires structural drag you can prove, not headwinds that compress margins 30-50 bps at $3.5B operating income.

April 22 earnings is the decision gate. Easy Q1 2025 comp + front-loaded inflation tailwind = slight upside asymmetry. If Q1 misses AND guidance comes down, revisit.

Factor Profile

250-day daily regression against SPY + MTUM:

Alpha (ann): -2.6%. Idio vol: 21.7%. Total vol: 22.1%. R-squared: 2.3%.

Comparison to confirmed removes:

Pattern for factor-based removes: idio <62%, MTUM beta < -0.27. ORLY is nowhere near either line. The anti-momentum is half the magnitude of even the weakest remove, and the idio variance is the highest in the basket. Removing ORLY on factor grounds would violate every prior precedent.

The Income Statement

All numbers verified against 10-K filed 2026-02-27 and Q4 2025 transcript (2026-02-05).

33 consecutive years of positive comps since IPO (10-K line 320). Professional comps >10% in Q3 and Q4 2025 (transcript line 41). DIY slightly negative traffic but positive ticket from same-SKU inflation.

Deep Dive: SG&A Is Structural

This is the real story. Not tariffs. Not the macro. The cost base is running hotter than management can forecast.

The Miss Pattern

Original FY2025 guide: 2-2.5% per-store SG&A growth (Q1 transcript line 93). Actual: 4.0%. Every single quarter overshot.

CFO Jeremy Fletcher (Q4 transcript, line 173): "has persisted longer than we would normally expect and has been a little bit of a story of increases on top of increases that we thought were already pretty dramatic."

FY2026 guide: 3-4%. Given the pattern, base case is 4%+.

Self-Insurance: The Hidden Accelerant

The 10-K buried the magnitude. Self-insurance reserves current portion — claims due within 12 months — nearly doubled.

Of the $174.7M total reserve increase, $147.9M (85%) went into the current portion. Most new reserves are near-term claims, not long-tail liabilities. 10% sensitivity = $44M = 1.4% of pretax income (10-K line 2553).

Payment schedule front-loaded: $297M in 2026, $68M in 2027, declining after (10-K line 2274). The cash hit is 2026.

Drivers per 10-K (line 2547): "general litigation accruals, inflation in claim development costs, our growing operations, increases in healthcare costs, the number of vehicles, and the number of hours worked." Per Fletcher (transcript line 133): "continued heightened cost inflation in our self-insurance programs, including headwinds in team member health care cost, workers' compensation and general claims expenses, litigation costs and auto liability reserves."

These are structural — fleet size, store count, healthcare inflation. They don't reverse.

Market Consensus vs Reality

What the Street Says

29 analysts: 5 strong buy, 18 buy, 5 hold, 1 sell. 79% bullish. Median target $108, mean $106 — both imply +15% upside. Targets clustered $105-$111. Everyone sees the same thing.

Post-Feb earnings analyst actions were all reiterations at $105-$111: Citi $110, JP Morgan $108, DA Davidson $110, RBC $109, Truist $107, Mizuho $105. No one changed their mind.

One outlier: $64 target (30% downside). That implies ≈18x forward earnings — someone thinks the margin story breaks.

The narrative: Best operator in auto parts. Buyback machine ($2B/yr). Defensive compounder. Professional business gaining share. Tariff beneficiary. Buy the dip near 52-week lows.

What the Street Is Missing

The forward multiple embeds margin recovery that management's own track record contradicts.

Forward P/E 25.73 at $91.93 implies EPS of $3.57. Trailing EPS $2.97. Required growth: 20.2%. Buybacks + revenue get you to ≈8.5%. The remaining 10-11% must come from margin expansion.

Where? SG&A is the only lever. Gross margin is already 51.6% — record levels, limited expansion room with professional mix shift (lower margin). Operating margin is flat at 19.5% despite gross margin gains. SG&A is absorbing all the improvement and then some.

Realistic FY2026 EPS: $3.20-$3.30 (8-10% growth from buybacks + revenue, flat margins). That puts the real forward P/E at 27.8-28.7x — full for a company with compressing margins, not the 25.7x the consensus models show.

The mispricing is ≈8-10% on forward earnings. Not dramatic. Not actionable at 0.41% weight.

Beat Rate Tells the Story

One beat in four quarters. 79% say Buy. The estimates are the mispricing — the Street keeps modeling the margin improvement that Fletcher keeps telling them isn't happening yet.

Insider Behavior

Small dollar amounts — these aren't panic exits. But nobody is buying. At 24% of the 52-week range, near the lows, no insider has put up a single dollar. Management's money disagrees with their narrative.

Tariff & China Exposure

China sourcing ≈25% of products, declining (Q1 2025 transcript, Brent Kirby, line 86). FY2025 same-SKU inflation under 3% full year, ≈6% in Q4 as tariff pricing ramped (transcript line 44). FY2026 guidance excludes incremental tariff changes (transcript lines 69-70).

Key detail: professional price increases are "hard-won" and sticky (transcript line 210). Industry doesn't roll back pricing even if tariff costs moderate. This is margin-protective. 2018 tariff precedent was industry non-event.

Tariff is a known risk, well-managed, affecting the entire sector proportionally. Not ORLY-specific.

Peer Context

*GPC P/E distorted by earnings issues.

ORLY is the clear sector winner. AZO and GPC have underperformed by 8-10pp more. AAP's rally is distress recovery (29.5% short interest), not comparable. The premium multiple (31x trailing vs AZO 24x) is earned by execution — 33 consecutive years of SSS growth, professional share gains, superior returns on capital.

Cash Flow & Buyback Machine

FCF decline is NOT operational. $560M renewable energy tax credit payment pulled into Q3 2025 (transcript line 160). FY2026 guide: $1.8-2.1B FCF.

Buyback avg price $92.26 vs current $91.93 — management buying at essentially current market. Diluted shares: 914.98M (FY2023) to 880.57M (FY2024) to 855.92M (FY2025). ≈2.6% annual reduction. Remaining authorization not disclosed in recent filings.

Balance sheet: $6.04B total debt, 2.03x adj debt/EBITDAR vs 2.5x target. Room to lever up. Shareholders' equity -$763M (buyback-driven, not distress). $1.94B debt maturing 2026, $850M already refinanced at 5.1% (March 2026 8-K).

Q1 2026 Setup (April 22 — Week 3 of Window)

Easy comp. Q1 2025 was the weakest quarter: EPS $0.62 (missed by 6%), SSS 3.6% (lowest of year), per-store SG&A 4.1% (worst of year), same-SKU inflation <0.5% (tariffs hadn't ramped).

Consensus: EPS $0.70 (+12.9% YoY). Management: "off to a solid start in 2026, in line with these expectations, supported by favorable winter weather in January" (transcript line 85). Guided SSS "high end" of 3-5% range for H1 (transcript line 84).

Asymmetry: Revenue likely beats (easy comp + inflation tailwind). SG&A likely exceeds guide again (structural drivers persist). Net: slight upside asymmetry to EPS, but not a high-conviction catalyst. If they beat, stock moves to $95-98 (max pain territory). If they miss again — two consecutive Q1 misses — narrative shifts to "maybe this isn't a dip."

Options Positioning

Per process rules: options data is color only. Prior memos had errors caught by review.

ATM IV 34.1% (133rd percentile vs 52-week 15-29%). IV/RV ratio ≈1.5 (options ≈50% rich vs realized). Post-earnings IV > pre-earnings IV — market pricing structural uncertainty beyond just the event. P/C OI ratio 0.16 (bullish institutional positioning). Max pain $95 (3.3% above current).

Filtration Math

At 0.41% weight:

For removal to add even 5 bps, ORLY must underperform average survivors by >12% in 15 weeks. That requires either: (a) a strong QQQ rally where beta 0.07 creates mechanical drag, or (b) an ORLY-specific negative catalyst. Neither is base case.

The anti-momentum loading (-0.19) is mild diversification. In a momentum reversal, ORLY outperforms the basket. At 0.41% it's not meaningful — but it argues for keep, not remove.

Systemic note: ORLY is one of 13 survivors with QQQ beta <0.5, totaling 11.0% of selectable weight. The low-beta drag is a portfolio-level issue requiring systematic treatment, not name-by-name removal.

Edge Assessment

Market cap: $77.6B. Coverage: 29 analysts. Short interest: 1.8%. Informational edge: Zero.

Every detail in this memo is available to every informed participant. The self-insurance reserve doubling is discussed on the earnings call. The SG&A miss pattern is visible to anyone with a calculator. The forward earnings gap is arithmetic. No undiscovered information exists at this market cap and coverage level.

Zero edge = market is approximately right = benchmark weight is correct.

The mild forward earnings mispricing (≈8-10%, stock at ≈28x real forward vs 25.7x consensus) is a 12-month story, not a 15-week filtration signal. And at 0.41%, it buys 3-5 bps even if you're right.

Invalidation Triggers (Would Change to FILTER)

• Q1 2026 EPS miss + guidance cut: Two consecutive Q1 misses + downward SG&A guidance = structural deterioration, not noise
• Tariff escalation >50% on Chinese auto parts imports: Disrupts supply chain, not just pricing
• Large litigation settlement from $297M reserve: Unexpected P&L hit beyond accruals
• Professional comp deceleration below 5%: Growth engine stalling removes the valuation premium thesis
• Broader momentum reversal: Would actually STRENGTHEN the keep case (anti-momentum = outperformance)

None present in current data.

Sources: ORLY 10-K (SEC, 2026-02-27) — primary [Tier 1]. ORLY Q4 2025 transcript (2026-02-05) [Tier 2]. ORLY Q1 2025 transcript (2025-04-24) [Tier 2]. Factor regression 250d SPY + MTUM [Quant]. yfinance ORLY, AZO, GPC, AAP (2026-03-27) [Market data]. Peer performance comparison [Calculated]. QQQ beta systemic analysis [Calculated].